Objective
Every organ harbours adult stem cells which have the potential for long-term replication, together with the capacities of self-renewal and multi-lineage differentiation. These stem cells function in tissue homeostasis and contribute to regeneration in response to injury. In addition, many cancers are caused by transforming mutations occurring in tissue-specific progenitor cells. These transformed stem cells harbour long-term proliferative potential and the ability to regenerate tumours consisting of phenotypically heterogeneous cell types. The identities of cancer stem cells (CSCs) that give rise to breast tumours are incompletely understood.
The mammary gland is composed of a complex cellular hierarchy, which undergoes most of its development postnatally. To achieve this great plasticity, both stem and progenitor cells play a pivotal role in the extensive tissue remodelling occurring during puberty and pregnancy. Deregulation of stem and progenitor cells is a key event in mammary carcinogenesis. Recently, the host laboratory identified a rare unipotent progenitor cell population in the adult murine mammary gland characterized by the surface protein leucine-rich repeat-containing G-protein coupled receptor 6 (Lgr6). Oncogenic mutations in Lgr6-positive cells led to the formation of luminal mammary gland tumours, and contributed to tumour aggressiveness and maintenance. Conversely, depletion of Lgr6-positive progenitors in mouse luminal breast cancer dramatically impaired tumour growth and morphology. However, the underlying molecular mechanisms driving these observations are unknown.
The aim of this project is the characterisation of Lgr6-positive breast cancer stem cells, using functional and molecular approaches. We will characterise the molecular differences between cancer stem cells and non-stem cells, with the ultimate goal of identifying novel therapeutic strategies to eliminate breast cancer stem cells.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine surgery
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences clinical medicine oncology breast cancer
- medical and health sciences clinical medicine obstetrics
- medical and health sciences basic medicine physiology homeostasis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2016
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
NW1 1AT London
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.